Inventor · disambiguated record
Olivier Alexis Georges Querolle
Also filed as: QUEROLLE OLIVIER · QUEROLLE OLIVIER ALEXIS GEORGES
33 granted patents·12 pending applications·234 citations·filing 2007–2022
96Inventor score
Top patents by PatentIndex Score
45 records- 0195US9850228B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Dec 26, 2017·17 cites·5 claims
- 0295US9464071B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 11, 2016·24 cites·45 claims
- 0395US9447098B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2013·Granted Sep 20, 2016·35 cites·20 claims
- 0494US9309242B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 12, 2016·26 cites·28 claims
- 0594US9303029B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 5, 2016·25 cites·20 claims
- 0694US9303030B2CompoundsASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 5, 2016·26 cites·21 claims
- 0793US9737544B2CompoundsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 22, 2017·15 cites·20 claims
- 0892US10052320B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 21, 2018·11 cites·20 claims
- 0992US10045982B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 14, 2018·11 cites·33 claims
- 1092US9493426B2Quinazolinone derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Nov 15, 2016·20 cites·20 claims
- 1190US10519137B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2017·Granted Dec 31, 2019·6 cites·18 claims
- 1285US10272087B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Apr 30, 2019·5 cites·21 claims
- 1384US10611778B2Fused bicyclic inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 7, 2020·3 cites·10 claims
- 1483US11530226B2Azepane inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Dec 20, 2022·1 cites·8 claims
- 1583US11396517B1Exo-aza spiro inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Jul 26, 2022·6 cites·13 claims
- 1680US10975100B2Fused bicyclic inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Apr 13, 2021·1 cites·6 claims
- 1777US2022135544A1Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1875US10745409B2Azepane inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Aug 18, 2020·1 cites·10 claims
- 1970US11220517B2Spiro bicyclic inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jan 11, 2022·1 cites·12 claims
- 2068US2023203011A1BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of CancerJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 2168US2020131153A1Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2266US11267804B2(R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activityJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Mar 8, 2022·0 cites·4 claims
- 2359US11186589B2Cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 30, 2021·0 cites·20 claims
- 2457US2023039917A1Exo-aza spiro inhibitors of menin-mll interactionJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 2556US2025002491A1N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancerFORX THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2656US2024425498A1Parg inhibitory compoundsFORX THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2755US12084462B2Spiro bicyclic inhibitors of menin-MLL interactionJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Sep 10, 2024·0 cites·14 claims
- 2855US2025333421A1Pyridazines or 1,2,4-triazines substituted by spirocyclic aminesJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 2955US2023250096A1SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVESJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 3055US2024417405A1Substituted Spiro DerivativesJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 3154US12473295B2Substituted straight chain spiro derivativesJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 18, 2025·0 cites·20 claims
- 3254US11542247B2Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancerJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Jan 3, 2023·0 cites·25 claims
- 3353US2019119299A1Cyanoindoline derivatives as nik inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 3448US11236084B2Substituted azaindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Feb 1, 2022·0 cites·15 claims
- 3544US10526316B2Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Jan 7, 2020·0 cites·12 claims
- 3642US11155555B2CompoundsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Oct 26, 2021·0 cites·18 claims
- 3741US2010081708A1Anticoagulant compoundsENDOTIS PHARMA·Filed 2007·Application pending·0 cites
- 3839US11180487B2Substituted cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Nov 23, 2021·0 cites·15 claims
- 3939US11136311B2Heteroaromatic derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Oct 5, 2021·0 cites·15 claims
- 4039US11130751B2Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Sep 28, 2021·0 cites·10 claims
- 4139US11001569B26-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted May 11, 2021·0 cites·8 claims
- 4239US2019263804A1Azabenzimidazole derivatives as pi3k beta inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 4338US10894793B2Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jan 19, 2021·0 cites·5 claims
- 4435US10202387B2Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Feb 12, 2019·0 cites·14 claims
- 4535US10087187B2Imidazopyridazine derivatives as PI3KB inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Oct 2, 2018·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Olivier Alexis Georges Querolle files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →